Association between beta-adrenoceptor antagonist-induced sympathicolysis and severity of coronary artery disease as assessed by coronary computed tomography angiography (CCTA)
Enhanced sympathetic nervous system activity is associated with increased mortality in many cardiac conditions including heart failure and coronary artery disease (CAD). To ensure adequate image quality of coronary CT angiography (CCTA), pre-scan β-adrenergic blockers (BB) are routinely administered. It is currently unknown whether sensitivity to sympathicolytic compounds is associated with severity of CAD. A total of 2633 consecutive patients (1733 [65.8%] men and 900 [34.2%] women, mean age 56.7 ± 11.5 years) undergoing CCTA for exclusion of significant CAD at our department between 06/2013 and 12/2016 were evaluated. Acute heart rate (HR) responses to BB administration were recorded in all patients. Coronary plaque burden as indicated by segment severity score (SSS), segment involvement score (SIS), and significant CAD (i.e. > 50% luminal narrowing) was higher in weak responders to BB as compared to strong responders to BB (p = 0.001 for SSS and SIS, and p = 0.021 for significant CAD). Accordingly, in a multiple linear regression model adjusted for known risk factors of CAD such as smoking, hypertension, diabetes and dyslipidaemia, as well as age, sex, body mass index (BMI), glomerular filtration rate, and HR during CCTA scan, a strong response to BB was selected as a significant independent negative predictor of coronary plaque burden (beta coefficient − 0.08, p = 0.001). We demonstrate that individuals with a weak acute response to BB administration encounter an increased risk of severe CAD. Taking into account sensitivity to sympatho-inhibition may add complementary information in patients undergoing CCTA for evaluation of CAD.
KeywordsCardiac sympathetic activity Cardiovascular risk Coronary computed tomography angiography
This study was supported by grants from the Iten-Kohaut Foundation, Switzerland (MM), the Swiss National Science Foundation (SNSF), the Olga Mayenfisch Foundation, Switzerland, the OPO Foundation, Switzerland, the Novartis Foundation, Switzerland, the Helmut Horten Foundation, Switzerland, and the Swissheart Foundation (CG).
Compliance with ethical standards
Conflict of interest
Michael Messerli received a research grant from the Iten-Kohaut Foundation, Switzerland. Catherine Gebhard received research grants from the Novartis Foundation, Switzerland. The University Hospital of Zurich holds a research contract with GE Healthcare. No further specific grants from funding agencies in the public, commercial, or not-for-profit sectors were received for this study.
Research involving human participants
The study was conducted in compliance with ICH-GCP-rules and the declaration of Helsinki and was evaluated and approved by the local ethics committee (BASEC No. 2017-01112).
The need for written informed consent was waived by the ethics committee due to the retrospective nature of the study.
- 1.World Health Organisation (2017) Cardiovascular disease statistic. WHO. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed 06 Sept 2018
- 3.American College of Cardiology Foundation Task Force on Expert Consensus D, Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC et al ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation Task Force on expert consensus documents. J Am Coll Cardiol. 2010;55(23):2663–2699CrossRefGoogle Scholar
- 6.Stocker TJ, Deseive S, Leipsic J, Hadamitzky M, Chen MY, Rubinshtein R et al (2018) Reduction in radiation exposure in cardiovascular computed tomography imaging: results from the PROspective multicenter registry on radiation dose estimates of cardiac CT angiography in daily practice in 2017 (PROTECTION VI). Eur Heart J 39(41):3715–3723CrossRefPubMedGoogle Scholar
- 13.Thrall G, Lane D, Carroll D, Lip GY (2007) A systematic review of the effects of acute psychological stress and physical activity on haemorheology, coagulation, fibrinolysis and platelet reactivity: implications for the pathogenesis of acute coronary syndromes. Thromb Res 120(6):819–847CrossRefPubMedGoogle Scholar
- 18.Al-Mallah MH, Qureshi W, Lin FY, Achenbach S, Berman DS, Budoff MJ et al (2014) Does coronary CT angiography improve risk stratification over coronary calcium scoring in symptomatic patients with suspected coronary artery disease? Results from the prospective multicenter international confirm registry. Eur Heart J Cardiovasc Imaging 15(3):267–274CrossRefPubMedGoogle Scholar
- 19.Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L et al (2012) Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (systolic heart failure treatment with the I(f) inhibitor ivabradine trial) study. J Am Coll Cardiol 59(22):1938–1945CrossRefPubMedGoogle Scholar
- 20.Dekker JM, Crow RS, Folsom AR, Hannan PJ, Liao D, Swenne CA et al (2000) Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: the ARIC Study. Atherosclerosis risk in communities. Circulation 102(11):1239–1244CrossRefGoogle Scholar
- 22.Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891–975CrossRefPubMedGoogle Scholar
- 30.Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt MJ, Holroyde MJ et al (2004) Mortality in patients after a recent myocardial infarction—a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 109(8):990–996CrossRefPubMedGoogle Scholar
- 33.Brugts JJ, Bertrand M, Remme W, Ferrari R, Fox K, MacMahon S et al (2017) The treatment effect of an ACE-inhibitor based regimen with perindopril in relation to beta-blocker use in 29,463 patients with vascular disease: a combined analysis of individual data of ADVANCE, EUROPA and PROGRESS trials. Cardiovasc Drugs Ther 31(4):391–400CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Min JK, Dunning A, Lin FY, Achenbach S, Al-Mallah M, Budoff MJ et al (2011) Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (Coronary CT angiography evaluation for clinical outcomes: an international multicenter registry) of 23,854 patients without known coronary artery disease. J Am Coll Cardiol 58(8):849–860CrossRefPubMedGoogle Scholar
- 37.Perski A, Olsson G, Landou C, Defaire U, Theorell T, Hamsten A (1992) Minimum heart-rate and coronary atherosclerosis—Independent relations to global severity and rate of progression of angiographic lesions in men with myocardial-infarction at a young age. Am Heart J 123(3):609–616CrossRefPubMedGoogle Scholar